ProBio vs WuXi AppTec

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/probio/wuxiapptec

Category	ProBio	WuXi AppTec
Listed site	both	cro
Summary	ProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.	Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Services	Analytical Method Development & Validation ICH Stability Studies In Vitro Pharmacology Protein Engineering Bioanalysis Flow Cytometry Services Immunogenicity Assays (ADA / NAb)	Discovery Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry Computational & In-Silico Drug Discovery Protein Engineering Preclinical In Vitro Studies In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Preclinical In Vivo Studies In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Carcinogenicity Studies DART (Reproductive & Developmental Toxicology) Specialized & Large-Animal Models Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Immunogenicity Assays (ADA / NAb) Biomarker Assays Flow Cytometry Services Clinical Trial Services Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy Analytical Method Development & Validation ICH Stability Studies Translational Research
Modalities	Biologics (Monoclonal Antibodies) Biologics (Other) mRNA Cell Therapy Gene Therapy Vaccine AAV / Viral Vector Platform	Small Molecule Peptide Oligonucleotide Biologics (Monoclonal Antibodies) Biologics (Other) Antibody-Drug Conjugate (ADC) mRNA Cell Therapy Gene Therapy Vaccine
Indications	Infectious Disease	Oncology Immunology Neurology Psychiatry Metabolic Cardiovascular Infectious Disease Rare Disease Respiratory Dermatology Ophthalmology Gastroenterology Nephrology Women's Health
Locations	United States, United States Netherlands, Netherlands South Korea, South Korea Hong Kong, Hong Kong, China Shanghai, Shanghai, China Nanjing, Nanjing, China	Headquarters, Shanghai, Pudong, China Global Operations, Asia, Europe, North America
Certifications	FDA · Identifier: US Food and Drug Administration EMA · Identifier: European Medicines Agency NMPA · Identifier: National Medical Products Administration	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.